retatrutide

Product

Heard on podcasts recently

An investigational once-weekly medication that activates GLP-1, GIP, and glucagon receptors and is being studied for obesity, diabetes, and related metabolic conditions.

Rank this week

—
Not in this week’s list

Share of the conversation

—

Reach this week

—

Tone this week

—

Not enough signal yet (fewer than 3 episodes scored).

Share of the conversation

Mentions of retatrutide per 1,000 mentions of anything, 7-day rolling, all podcasts.

0.0‰0.1‰0.2‰0.3‰Aug 25Sep 16Oct 9Oct 31Nov 22
Show the data
DayShare (7-day)Mentions
Aug 250.06‰1
Sep 10.03‰3
Sep 30.07‰4
Sep 80.07‰2
Sep 100.05‰3
Sep 140.06‰1
Sep 210.01‰1
Sep 280.02‰2
Oct 10.03‰1
Oct 140.01‰1
Oct 150.02‰1
Oct 160.03‰1
Oct 200.04‰2
Oct 280.06‰7
Oct 290.09‰4
Oct 300.13‰4
Nov 20.21‰10
Nov 30.22‰1
Nov 50.15‰3
Nov 120.02‰2
Nov 130.04‰3
Nov 200.01‰1
Nov 210.04‰4

Who is saying what about retatrutide

Verified quotes from the last 90 days: who made the most claims, and which way they leaned.

Discussed alongside

Names that come up in the same conversations as retatrutide.

See 5 more with Pro

Embed this

Paste this on your site to show retatrutide's current trend:

<iframe src="https://podlume.ai/embed/e/product-retatrutide" width="360" height="220" style="border:0" loading="lazy" title="retatrutide on PodLume Trends"></iframe>